NELARABINE
Generic: NELARABINE
Zydus Lifesciences LimitedManufacturer
INTRAVENOUSRoute
NELARABINEActive Substance
2021-11-17Original Approval
NELARABINE is FDA application ANDA215037, sponsored by ZYDUS PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2025-02-13
Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1839-1; b) 6 x 50 mL SingFailed Impurities/Degradation Specifications
Class II2025-02-13
Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1726-1; b) 6 x 50 mL SingFailed Impurities/Degradation Specifications
Top Reported Reactions
1
DRUG INEFFECTIVE
65 reports
2
FEBRILE NEUTROPENIA
55 reports
3
NEUROTOXICITY
53 reports
4
OFF LABEL USE
52 reports
5
PERIPHERAL SENSORY NEUROPATHY
50 reports
6
MYELOPATHY
47 reports
7
SEPSIS
45 reports
8
NEUROPATHY PERIPHERAL
43 reports
9
NEUTROPENIA
41 reports
10
MUSCULAR WEAKNESS
40 reports